USF Researcher Develops Therapeutic Vaccine to Combat Alzheimer’s Disease and Neurodegenerative Disorders

TAMPA, Fla., January 19, 2017 — Alzamend Neuro™ has licensed the USF treatment to help advance commercialization. A neuroscientist at the USF Health Byrd Alzheimer’s Institute and the USF College of Pharmacy has developed an immunotherapeutic treatment now undergoing testing for the prevention, treatment and cure of Alzheimer’s disease as well as other neurological disorders. This innovative technology has been exclusively licensed from USF to Alzamend Neuro™, Inc.

Chuanhai Cao, a USF associate professor of pharmaceutical sciences and a researcher at the USF Health Byrd Alzheimer’s Institute, has focused his research on peptides for use as a vaccine for Alzheimer’s disease and other neurological diseases.

Dr. Cao has developed an antigen activated immune cell-based vaccine that shows promise in helping combat nervous system dysfunctions in Alzheimer’s disease. Research has shown that the therapeutic vaccine can target the toxic protein in the brain and fix the impaired immune system in several Alzheimer’s mouse models.

“Our research team has developed a therapeutic vaccine that can both combat the disease and improve the immune system,” Cao said. “The most recent results have proved that such therapy can improve memory and avoid an unwanted vaccine associated reaction in a mouse model, so it could be a very promising therapeutic for Alzheimer’s disease patients.”

FULL ARTICLE